Article
Alunbrig Approved for the Treatment of ALK+ Metastatic Non-Small Cell Lung Cancer, Available for Order at Biologics, Inc.
Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, has been selected by Takeda Pharmaceutical Company Limited to be a specialty pharmacy provider as part of the distribution network for Alunbrig.
CARY, N.C. (May 11, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, has been selected by Takeda Pharmaceutical Company Limited, through its wholly-owned subsidiary ARIAD Pharmaceuticals, Inc., to be a specialty pharmacy provider as part of the distribution network for ALUNBRIGTM(brigatinib).
ALUNBRIG, an oral therapy for the treatment of patients with anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib, received Accelerated Approval by the U.S. Food and Drug Administration (FDA) on April 28, 2017. This Accelerated Approval was based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
ALUNBRIG previously received Breakthrough Therapy Designation and was granted Orphan Drug Designation by the FDA.
NSCLC is the most common form of lung cancer, making up 85% of new lung cancer cases in the U.S. each year. Approximately 2-8% of these patients have a rearrangement in the ALK gene.1
“We are thrilled to have been given the privilege of being in this network of specialty pharmacies dispensing ALUNBRIG,” said Brandon Tom, vice president, Biopharma Services, Biologics, Inc. “Our team has decades of experience supporting NSCLC patients. We’re well prepared to help patients transition to this new therapy and to support them throughout their entire treatment journey.”
ALUNBRIG is manufactured by Takeda Pharmaceutical Company Limited through its wholly-owned subsidiary ARIAD Pharmaceuticals, Inc. Full prescribing information for ALUNBRIG is available at www.ALUNBRIG.com.
Biologics’ oncology specialty pharmacy is supported by a multidisciplinary care team that includes a pharmacist, oncology nurse and financial counselor. Individualized care plans are developed to address the unique needs of each patient and to streamline communication back to the treating provider.
Physicians may submit prescriptions to Biologics via phone (800.850.4306), fax (800.823.4506) or eScribe. For electronic prescribing systems, physicians may search for Biologics within their EMR system.
